Baseline subfoveal choroidal thickness as an indicator for bevacizumab outcomes in central retinal vein occlusion

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

SALEHI ALI; ABTAHI MOHAMMAD ALI; ABTAHI SEYED HOSSEIN; Razmjou Hasan; TOHIDI MOHAMMAD; AKBARI MOJTABA; JAHANBANI ARDAKANI HAMIDREZA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Tehran University Medical Journal Year:2019 | Volume:77 | Issue:5 Page(s): 288-293

Download Full-Text

Persian Verion

View:

337

Download:

Cites:

Information Journal Paper

Title

Baseline subfoveal choroidal thickness as an indicator for bevacizumab outcomes in central retinal vein occlusion

Author(s)

Keywords

bevacizumabQ1

choroidQ1

cohort studiesQ1

endothelial growth factorsQ1

intravitreal injectionsQ1

optical coherence tomographyQ1

retinal vein occlusionQ3

visual acuityQ3

Abstract

Background: retinal vein occlusions are one of the most common form of retinal vascular disorders and could lead to vision loss due to macular edema, macular ischemia and sequelae from neovascularization. Anti-venous endothelial growth factor (anti-VEGF) treatment is the choice strategy of treatment for patients with macular edema secondary to central retinal vein occlusion (CRVO). There is an evidence of body with the controversies regarding increment of choroidal thickness in CRVO condition. The current study was designed to determine whether baseline subfoveal choroidal thickness may be an indicator for visual and anatomical outcome of bevacizumab in patients with CRVO macular edema. Methods: This study was a prospective clinical cohort study that enrolled in 23 new cases of treatment-naï ve central retinal vein occlusion (CRVO) from February to July 2017 who were visited in Feiz Eye Hospital, Isfahan, Iran. Patients received a single injection of bevacizumab and were followed for 30 days. Ratio of subfoveal choroidal thickness (SFCT) was measured using enhanced depth imaging spectral-domain optical coherence tomography (EDI-OCT). Ratio of SFCT of the CRVO eye to the fellow healthy eye (SFCT1/F) was taken as independent variable. Changes of best-corrected visual acuity (BCVA) in LogMAR (Δ BCVA, functional response) and secondary to baseline central macular thickness ratio (CMT2/1, anatomical response) in the CRVO eyes were taken for comparative and correlative analytics. Results: A total of 46 eyes from 23 patients with the mean age of 64. 60± 10. 19 years were included in this study. Baseline SFCT was higher in CRVO eyes (251. 91± 46. 09 μ m) in comparison to the fellow eye (206. 95± 26. 62, P<0. 0001). Also central macular thickness in CRVO eyes were significantly higher in CRVO eyes in comparison with fellow eye (531. 04± 38. 22 vs 303. 30± 33. 59, respectively, P<0. 05). SFCT1/F, correlated moderately with anatomical (CMT2/1) and strongly with functional response (Δ BCVA). Conclusion: Bilateral evaluation of SFCT by EDI-OCT in all newly diagnosed CRVO cases is recommended to determine if there is a relative increase in choroidal thickness. This may help predict short-term response to anti-VEGF therapy.

Cites

No record.

References

Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema

Cite

APA: Copy

SALEHI, ALI, ABTAHI, MOHAMMAD ALI, ABTAHI, SEYED HOSSEIN, Razmjou, Hasan, TOHIDI, MOHAMMAD, AKBARI, MOJTABA, & JAHANBANI ARDAKANI, HAMIDREZA. (2019). Baseline subfoveal choroidal thickness as an indicator for bevacizumab outcomes in central retinal vein occlusion. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), 77(5 ), 288-293. SID. https://sid.ir/paper/406291/en

Vancouver: Copy

SALEHI ALI, ABTAHI MOHAMMAD ALI, ABTAHI SEYED HOSSEIN, Razmjou Hasan, TOHIDI MOHAMMAD, AKBARI MOJTABA, JAHANBANI ARDAKANI HAMIDREZA. Baseline subfoveal choroidal thickness as an indicator for bevacizumab outcomes in central retinal vein occlusion. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ)[Internet]. 2019;77(5 ):288-293. Available from: https://sid.ir/paper/406291/en

IEEE: Copy

ALI SALEHI, MOHAMMAD ALI ABTAHI, SEYED HOSSEIN ABTAHI, Hasan Razmjou, MOHAMMAD TOHIDI, MOJTABA AKBARI, and HAMIDREZA JAHANBANI ARDAKANI, “Baseline subfoveal choroidal thickness as an indicator for bevacizumab outcomes in central retinal vein occlusion,” TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), vol. 77, no. 5 , pp. 288–293, 2019, [Online]. Available: https://sid.ir/paper/406291/en

Related Journal Papers